Table 1.
Comparative analysis of clinical data between the EM group and the NEM group
| Variable | Description | Total (N = 236) | EM group (N = 41) | NEM group (N = 195) | P Value |
|---|---|---|---|---|---|
| Sex | Male | 194 (82.2%) | 34 (82.9%) | 160 (82.1%) | 1.000 |
| Female | 42 (17.8%) | 7 (17.1%) | 35 (17.9%) | ||
| Age(years) | 55.4 ± 12.8 | 49.8 ± 13.5 | 56.5 ± 12.3 | .002 | |
| Charlson comorbidity index | 2.4 ± 1.5 | 3.0 (1.0 to 3.0) | 2.0 (1.0 to 3.0) | .590 | |
| ASA classification | 1 | 56 (23.7%) | 10 (24.4%) | 46 (23.6%) | .835 |
| 2 | 162 (68.6%) | 27 (65.9%) | 135 (69.2%) | ||
| 3 | 18 (7.6%) | 4 (9.8%) | 14 (7.2%) | ||
| Abdominal surgery history | Yes | 34 (14.4%) | 4 (9.8%) | 30 (15.4%) | .491 |
| No | 202 (85.6%) | 37 (90.2%) | 165 (84.6%) | ||
| HBV infection | Yes | 203 (86.0%) | 37 (90.2%) | 166 (85.1%) | .541 |
| No | 33 (14.0%) | 4 (9.8%) | 29 (14.9%) | ||
| Child–Pugh grade | A | 218 (92.4%) | 34 (82.9%) | 184 (94.4%) | .029 |
| B | 18 (7.6%) | 7 (17.1%) | 11 (5.6%) | ||
| BCLC staging | 0 | 37 (15.7%) | 2 (4.9%) | 35 (17.9%) | <.001 |
| A | 136 (57.6%) | 19 (46.3%) | 117 (60%) | ||
| B | 41 (17.4%) | 6 (14.6%) | 35 (17.9%) | ||
| C | 22 (9.3%) | 14 (34.1%) | 8 (4.1%) | ||
| Tumor burden score | 5.8 ± 4.0 | 8.2 (5.1 to 13.0) | 4.3 (2.7 to 6.3) | <.001 | |
| Tumor number | Single | 177 (75.0%) | 25 (61%) | 152 (77.9%) | .001 |
| Double | 30 (12.7%) | 4 (9.8%) | 26 (13.3%) | ||
| Multiple | 29 (12.3%) | 12 (29.3%) | 17 (8.7%) | ||
| Maximum tumor diameter | 5.5 ± 4.1 | 8.0 (5.0 to 13.0) | 4.0 (2.3 to 6.0) | <.001 | |
| AFP | ≤ 400 μg/L | 166 (70.3%) | 20 (48.8%) | 146 (74.9%) | .002 |
| > 400 μg/L | 70 (29.7%) | 21 (51.2%) | 49 (25.1%) | ||
| NLR | 3.0 ± 1.5 | 3.0 (2.2 to 4.1) | 2.6 (1.9 to 3.5) | .117 | |
| Anatomical hepatectomy | Yes | 167 (70.8%) | 35 (85.4%) | 132 (67.7%) | .038 |
| No | 69 (29.2%) | 6 (14.6%) | 63 (32.3%) | ||
| Resection extent | Major | 108 (45.8%) | 33 (80.5%) | 75 (38.5%) | <.001 |
| Minor | 128 (54.2%) | 8 (19.5%) | 120 (61.5%) | ||
| Operation duration (min) | 342.6 ± 159.7 | 372.0 (318.0 to 498.0) | 306.0 (220.5 to 387.0) | <.001 | |
| Operation blood loss (ml) | 861.4 ± 1065.8 | 700.0 (500.0 to 1000.0) | 500.0 (300.0 to 1000.0) | .037 | |
| Textbook Outcome | Yes | 144 (61.0%) | 10 (24.4%) | 134 (68.7%) | <.001 |
| No | 92 (39.0%) | 31 (75.6%) | 61 (31.3%) | ||
| Microvascular Invasion | Yes | 98 (41.5%) | 31 (75.6%) | 67 (34.4%) | <.001 |
| No | 138 (58.5%) | 10 (24.4%) | 128 (65.6%) | ||
| Degree of inflammation and necrosis(G) | 0/1 | 58 (24.6%) | 8 (19.5%) | 50 (25.6%) | .529 |
| 2/3/4 | 178 (75.4%) | 33 (80.5%) | 145 (74.4%) | ||
| Degree of fibrosis(S) | 0/1 | 52 (22.0%) | 7 (17.1%) | 45 (23.1%) | .525 |
| 2/3/4 | 184 (78.0%) | 34 (82.9%) | 150 (76.9%) | ||
| Postoperative hospital stay | 13.2 ± 8.9 | 15.0 (11.0 to 20.0) | 10.0 (7.0 to 15.0) | <.001 |
ASA classification, American Society of Anesthesiologists Physical Status Classification; HBV infection, Hepatitis B Virus infection; BCLC staging, Barcelona Clinic Liver Cancer staging system; NLR, Neutrophil-to-Lymphocyte Ratio